Abstract: The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering one or more sesquiterpene lactones of the thapsigargin family produced in (a). The present invention further relates to a suspension cell culture comprising plant cells of the genus Thapsia, wherein the plant cells are capable of producing one or more sesquiterpene lactones of the thapsigargin family and to a plant cell biomass comprising plant cells of the genus Thapsia obtained from said suspension cell culture.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A powder inhaler for administering powder by inhalation comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A powder inhaler for administering powder by inhalation comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A blister pack unit for a powder inhaler, comprising a body which includes a plurality of surfaces which each includes a plurality of blisters (21, 22) containing powder containing medicament and are rotationally symmetrically disposed about an imaginary axis.

Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entrainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: A powder inhaler for administering powder by inhalation, comprising: a flow path defined by a plurality of surfaces through which a stream of air is in use drawn on inhalation by a user; and dosing means (18) for providing a dose of powder to the flow path for entertainment in the stream of air; characterized in that the inhaler further comprises dislodging means for dislodging powder accumulated on a surface of the flow path downstream of the dosing means (18).

Abstract: The invention provides a pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance; an its use in the treatment or prophylaxis of disorders of the intestines, rectum or vagina.

Abstract: The invention provides a unit formulation which comprises a 2-hydroxy-5-phenylazobenzoic acid derivative which is particularly sodium balsalazide dihydrate which formulation has a density of at least 0.9 mg/mm3 and its use in the treatment of gastrointestinal diseases.